Translate page

-- Virtual Education Program: 2014 Edition

giorasharf  

Non-adherence of CML patients
Results of the global adherence survey of the CML Advocates Network
Giora Sharf, CML Advocates Network

  • Results of the global adherence survey of 2546 CML patients from 79 countries
  • Intentional and non-intentional non-adherence levels
  • Differences between countries, type of TKI, administration schedule, age groups, perception of quality of life and side effects
  • Tools to drive adherence and importance of routines

-- Virtual Education Program: 2012 Edition

(We are very grateful for the support of Brandcast media to produce these web streams)

jane-apperley  

Pregnancy in Chronic Myeloid Leukemia
Jane Apperley, Imperial College London, UK

  • Effect of CML and its treatments on fertility of women and men
  • Effect of pregnancy on CML and its treatment
  • Effect of CML and CML treatments on pregnancy
  • Timing of pregnancy in relation to diagnosis of CML
  • Case studies of pregnancies
delphine-rea    

Can we safely stop TKI therapies? Experience from the STOP trials

Delphine Rea, Hôpital Saint-Louis, Paris, France

  • Unmet medical needs in currently available CML treatments
  • Treatment options for CML with T315I mutation
  • Treatment options after TKI intolerance
  • Trial results with bosutinib, ponatinib, omacetaxine
  • Results from studies investigating imatinib + interferon
jorge-cortes-en  

New Drugs in the Treatment of CML

Jorge Cortes, MD Anderson Cancer Center, Houston, USA

  • Unmet medical needs in currently available CML treatments
  • Treatment options for CML with T315I mutation
  • Treatment options after TKI intolerance
  • Trial results with bosutinib, ponatinib, omacetaxine
  • Results from studies investigating imatinib + interferon

 

-- Virtual Education Program: 2011 Edition

(We are very grateful for the support of Brandcast media to produce these web streams)

vep_branford_molecmonitoring  

The Importance of Molecular Monitoring in CML

Susan Branford, Australia 

  • Measurement of BCR-ABL transcript levels to assess residual disease
  • Recommended monitoring for CML
  • The significance of achieving a major molecular response
vep_branford_mutationanalysis    

The importance of BCR-ABL kinase domain mutation analysis in CML

 Susan Branford, Australia

  • Mutations as a mechanism of imatinib resistance
  • Why mutations arise
  • When to test for mutations
  • Therapeutic options in the presence of mutations
vep_radich_transplant  

Transplantation for CML in 2011: Who, why, when?

Jerry Radich, Seattle, USA

  • Definition of optimal response to imatinib
  • Managing suboptimal response, case study
  • Adherence and molecular response
  • Role of mutations, criteria for mutation screening on 1st line therapy
  • Dose related toxicities with TKI’s; concomitant medications
   

 

 

Click here to see the Virtual Education Program modules of 2010, featuring John Goldman, Michele Baccarani, Tim Hughes and Pat Garcia-Gonzalez.

 

 

-- Virtual Education Program: 2010 Edition

(We are very grateful for the support of Brandcast media to produce these web streams)

edu-goldman  

CML Treatment with imatinib

John Goldman, London, UK

  • Biology and mechanisms of CML
  • Mechanism of action of imatinib
  • Results of the IRIS study
  • Adverse effects of imatinib
  • Methods to detect residual disease
  • Imatinib in children and in pregnancy
edu-baccarani  

European LeukemiaNet (ELN) recommendations 2009

Michele Baccarani, Bologna, Italy

  • Predicting response to imatinib
  • Depth of response, does it matter?
  • Primary and secondary failure to imatinib
  • How to monitor response
  • Treatment recommendations
edu-hughes  

Optimising Response and Managing Resistance to Treatment

Tim Hughes, Adelaide, Australia

  • Definition of optimal response to imatinib
  • Suboptimal response
  • Considerations for managing suboptimal response, case study
  • Adherence and molecular response
  • Role of mutations, criteria for mutation screening on first line therapy
  • Dose related toxicities with TKI’s; concomitant medications
edu-cortes  

Treatment of patients after first line therapy

Jorge Cortes, Houston, USA

  • Survival post imatinib
  • Treatment with second generation TKIs (2nd line and 1st line)
  • Optimal time to switch therapy
  • Strategies to prevent imatinib failure
  • Role of interferon and transplantation
  • Presentation of new agents under investigation
discussion-hughes-garciagonzalez  

Practical recommendations for
the management of CML patients:

Interview with Prof. Timothy Hughes

conducted by Pat Garcia-Gonzalez, Executive Director of The Max Foundation